The Latest Breaking News from Abbott Laboratories

Abbott is poised to release its second-quarter results this month, and analysts are projecting a slight increase in profits.

The healthcare industry is set to grow significantly due to technological advances, an aging population, and increasing demand for quality healthcare. To that end, it could be wise to buy fundamentally strong healthcare stocks like Abbott Laboratories (ABT), Stryker (SYK), and Centene (CNC), which are set to benefit from these…

Abbott has underperformed the broader market over the past year, but Wall Street analysts are optimistic about the stock’s prospects.

These three Dividend Aristocrats trade near oversold levels and offer reliable income and potential capital appreciation.

Pharmaceutical equipment firms are funding NHS staff and training while promoting sales

Abbott Laboratories surpasses profit expectations with strong medical device sales, showcasing market leadership and growth strategies.

Abbott Laboratories came in Wednesday with a "solid" first-quarter report that included a guidance raise, but Abbott stock slipped.

These three stocks have earned the title of Dividend Kings by consistently increasing dividends for at least 50 years.

Abbott Laboratories' Q4 earnings report and stock performance analysis, highlighting limited growth potential.